Interestingly, the protective effect of CMV is conditional upon BRAF mutation status, with significantly fewer BRAF-mutated CMV+ patients with MM observed than expected, whereas BRAF-WT MM presented later in CMV+ individuals. The gene discussed is BRAF; the disease is Miyoshi myopathy.